<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002669'>Osteosarcoma</z:hpo>, one of the most frequent <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">secondary malignancies</z:e> after the treatment of young patients with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, has only very rarely been observed in association with hematopoietic stem cell transplantation (HSCT) </plain></SENT>
<SENT sid="1" pm="."><plain>We report four patients who were identified by searching the database of the Cooperative <z:hpo ids='HP_0002669'>Osteosarcoma</z:hpo> Study Group (COSS) for patients whose <z:hpo ids='HP_0002669'>osteosarcoma</z:hpo> arose following HSCT </plain></SENT>
<SENT sid="2" pm="."><plain>Transplant indications had been <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (3). and <z:e sem="disease" ids="C0002895" disease_type="Disease or Syndrome" abbrv="">sickle cell disease</z:e> (1). and the stem cell source was bone marrow in <z:hpo ids='HP_0000001'>all</z:hpo> cases (three allogeneic, one syngeneic) </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> four had received chemotherapy with alkylators as part of their conditioning regimen and/or first line therapy </plain></SENT>
<SENT sid="4" pm="."><plain>The conditioning regimen included total body irradiation in three patients </plain></SENT>
<SENT sid="5" pm="."><plain>The <z:hpo ids='HP_0002669'>osteosarcomas</z:hpo> arose at the age (adolescence) and sites (around the knee) typical for the disease </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> four patients received chemotherapy as part of multimodal <z:hpo ids='HP_0002669'>osteosarcoma</z:hpo> treatment, and <z:hpo ids='HP_0000001'>all</z:hpo> four are currently alive, three in continuous remission at 5 7/12, 2 11/12, and 0 6/12 years and one with relapsed <z:hpo ids='HP_0002669'>osteosarcoma</z:hpo> at 4 1/12 years </plain></SENT>
<SENT sid="7" pm="."><plain>One of the <z:hpo ids='HP_0002669'>osteosarcoma</z:hpo>-free survivors suffered a third <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e>, <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0002669'>Osteosarcoma</z:hpo> should be included among the <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">secondary malignancies</z:e> that can arise following HSCT </plain></SENT>
<SENT sid="9" pm="."><plain>Multi-modal therapy according to guidelines for de novo <z:hpo ids='HP_0002669'>osteosarcoma</z:hpo> can lead to long-term survival in selected patients </plain></SENT>
</text></document>